Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

TScan Therapeutics (TCRX) Net Margin (2020 - 2025)

Historic Net Margin for TScan Therapeutics (TCRX) over the last 6 years, with Q3 2025 value amounting to 1422.14%.

  • TScan Therapeutics' Net Margin rose 14269500.0% to 1422.14% in Q3 2025 from the same period last year, while for Sep 2025 it was 1680.02%, marking a year-over-year decrease of 4911400.0%. This contributed to the annual value of 4488.96% for FY2024, which is 40651000.0% down from last year.
  • TScan Therapeutics' Net Margin amounted to 1422.14% in Q3 2025, which was up 14269500.0% from 1201.3% recorded in Q2 2025.
  • TScan Therapeutics' Net Margin's 5-year high stood at 271.99% during Q4 2023, with a 5-year trough of 5906.9% in Q2 2024.
  • Moreover, its 5-year median value for Net Margin was 604.94% (2022), whereas its average is 1548.87%.
  • In the last 5 years, TScan Therapeutics' Net Margin tumbled by -51430800bps in 2024 and then soared by 47056000bps in 2025.
  • Quarter analysis of 5 years shows TScan Therapeutics' Net Margin stood at 497.55% in 2021, then fell by -22bps to 604.94% in 2022, then soared by 55bps to 271.99% in 2023, then crashed by -1820bps to 5220.9% in 2024, then surged by 73bps to 1422.14% in 2025.
  • Its Net Margin was 1422.14% in Q3 2025, compared to 1201.3% in Q2 2025 and 1571.95% in Q1 2025.